Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Acrotech Biopharma to acquire portfolio of seven marketed oncology injectable products from Spectrum Pharmaceuticals

Posted On: 2019-01-17 18:26:52

Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo"), announces the signing of a definitive agreement to acquire a portfolio of seven branded oncology injectable products from Spectrum pharmaceuticals Inc. The acquisition also brings-in an experienced branded commercial infrastructure in the US.

Acrotech Biopharma LLC ("Acrotech"), a wholly-owned subsidiary of Aurobindo Pharma USA Inc., which in turn a wholly-owned subsidiary of Aurobindo Pharma Limited, will be acquiring the portfolio on a debt free and cash free basis. This acquisition is in line with our strategy to commercialize innovative proprietary medications.

The acquisition will help Aurobindo Group to enter the branded oncology market with a range of products which are well recognized by the oncology community. Aurobindo Group will also acquire a well-established and experienced branded commercial infrastructure to continue commercializing these brands.

Commenting on the transaction, Dr. Ashish Anvekar, President of Acrotech, said: "We are excited to jump-start our mission of helping cancer patients across the globe by delivering clinically differentiated medications and leveraging strategic partnerships. We look forward to welcome an experienced team of employees from Spectrum who are essential to our mission."

Commenting on the transaction, Mr. N. Govindarajan, Managing Director of Aurobindo, said: "The acquisition announced today creates an ideal launch pad for Acrotech, and establishes our presence in the branded market, which is in line with our strategy to grow and diversify our business in the US."

Mr. Govindarajan added, "We look forward to deliver the benefits of this transaction to all our stakeholders including employees, patients, customers and healthcare providers across the US."

The transaction is expected to close within 90 days of signing following the completion of customary as well as regulatory conditions, including FTC clearance.

This announcement does not constitute a recommendation to shareholders or potential investors.

Leerink Partners LLC acted as financial advisor and Reed Smith LLP acted as legal counsel to Aurobindo.

Shares of AUROBINDO PHARMA LTD. was last trading in BSE at Rs.774.25 as compared to the previous close of Rs. 787.05. The total number of shares traded during the day was 88331 in over 1348 trades.

The stock hit an intraday high of Rs. 791.75 and intraday low of 769.55. The net turnover during the day was Rs. 68995503.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Ajmera Realty and Infra India Ltd awarded Developer of the Year - Residential category award

CARE reaffirms ratings of Chaman Lal Setia Exports Ltd

Hon'ble NCLAT upholds the Resolution Plan of MBL Infra

Avana's Water Conservation Solution Becomes Best CSR Idea Of The Year

Coffee Day Enterprises Ltd update On Debt Position

Mahindra inaugurates its 1st automotive assembly plant in Sri Lanka, expands global footprint

TVS Motor Singapore invests US$ 3.2 Million in Predictronics Corporation

NACL Industries Ltd reports financial results for Q1 FY20

Precision Camshafts Limited - Q1 FY2020 results

SREI Equipment Finance Ltd's NCD issue opens on Aug 16, 2019

Transform Banking with Newgen at FIBAC 2019

Hero MotoCorp surpasses milestone of 1000 women employees

Sun Pharma and China Medical System Holdings Enter into Licensing Agreement for Generic Products in Mainland China

IFIN & RCFL initiate proceedings against SKIL Infrastructure Ltd

Kridhan Infra Limited - VNC wins new orders worth INR 145 Crores

Ram Ratna Wires Ltd fixes Aug 30, 2019 as record date for dividend

Himatsingka Seide Ltd clarifies on certain media reports

Master Trust Ltd fixes Aug 27, 2019 as record date for sub-division of equity shares

Advik Laboratories Ltd Board to consider sale of manufacturing unit

CARE downgrades ratings of Walchandnagar Industries Ltd

Super Crop Safe Limited announces Financial Results for Q1FY20

Info Edge India Ltd to invest in Shopkirana

Hinduja Ventures Ltd board to consider reorganizaiton of businesses on Aug 23, 2019

Voltas launches new Brand Shop at Gajuwaka, Visakhapatnam

CRISIL downgrades ratings of DCM Ltd

Lupin receives U.S. FDA approval for Hydrocortisone Valerate Cream

Birlasoft Wins Two Oracle Excellence Awards for 2019

TCS Interactive Wins 2019 Red Dot: Best of the Best Award in Brands and Communication Design

Blue Star Ltd - Financial Highlights for Q1 FYF20

Hindustan Foods Ltd - Q1-FY20 Performance Highlights

Omaxe Ltd Consolidated PAT for Q1 FY19-20 at Rs 14.91 cr

QGO Finance Ltd board to consider NCD issue on Aug 21, 2019

Mindteck reports financial results for Q1 2019-20

Ramkrishna Forgings Ltd's resolution plan for ACIL Ltd accepted

KNR Constructions Ltd to sell stake in SPV for Rs. 95.79 crores

Panacea Biotec announces Q1 FY20 results

IOB offers Retail Loans through the online portal PSB Loans in 59 minutes.com

Travel Money with YES BANK to launch Forex Card on Visa network

Mishtann Foods reports 22.1% increase in Q1FY2020 PAT at INR 3.14 crore

India Ratings assigns 'Ind AA- / Negative' For Indian Overseas Bank Bonds

YES BANK raises Rs. 1,930 crores through Qualified Institutions Placement route

Hero MotoCorp Ltd updates on closure of production facilities

Voltas Beko launches India's first 5 Star rated Washing Machines

Titagarh Wagons Ltd consortium bags order for Pune Metro Rail project

PVR launches sub-brand PVR UTSAV in Satna

Brigade Enterprises Ltd fixes Aug 29, 2019 as record date for bonus issue

India Infoline Finance announces consolidated PAT of Rs. 181 crore

West Coast Paper Mills Limited : Q1FY20 Results

Dynacons Systems & Solutions Ltd Board approves interim dividend of Rs. 0.50

Man Industries India Limited reports Q1FY20 Financial Results







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019